JP2016519761A - 好中球細胞外トラップにおけるプロテアーゼの基質プロファイリング - Google Patents

好中球細胞外トラップにおけるプロテアーゼの基質プロファイリング Download PDF

Info

Publication number
JP2016519761A
JP2016519761A JP2016502967A JP2016502967A JP2016519761A JP 2016519761 A JP2016519761 A JP 2016519761A JP 2016502967 A JP2016502967 A JP 2016502967A JP 2016502967 A JP2016502967 A JP 2016502967A JP 2016519761 A JP2016519761 A JP 2016519761A
Authority
JP
Japan
Prior art keywords
sample
subject
protease
net
neutrophil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519761A5 (enExample
Inventor
ジン，イエ
マーフイー，ジヨン
ハーミストン，テリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of JP2016519761A publication Critical patent/JP2016519761A/ja
Publication of JP2016519761A5 publication Critical patent/JP2016519761A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016502967A 2013-03-15 2014-03-14 好中球細胞外トラップにおけるプロテアーゼの基質プロファイリング Pending JP2016519761A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799658P 2013-03-15 2013-03-15
US61/799,658 2013-03-15
PCT/US2014/029040 WO2014144572A2 (en) 2013-03-15 2014-03-14 Substrate profiling of proteases in neutrophil extracellular traps

Publications (2)

Publication Number Publication Date
JP2016519761A true JP2016519761A (ja) 2016-07-07
JP2016519761A5 JP2016519761A5 (enExample) 2017-04-06

Family

ID=51538342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502967A Pending JP2016519761A (ja) 2013-03-15 2014-03-14 好中球細胞外トラップにおけるプロテアーゼの基質プロファイリング

Country Status (7)

Country Link
US (1) US9958459B2 (enExample)
EP (1) EP2997352A4 (enExample)
JP (1) JP2016519761A (enExample)
CN (1) CN105339780A (enExample)
CA (1) CA2906124A1 (enExample)
HK (1) HK1214863A1 (enExample)
WO (1) WO2014144572A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3607320A4 (en) * 2017-04-03 2021-04-21 The Regents of the University of California COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer
CA3181285A1 (en) * 2020-07-20 2022-01-27 Jessica BASSO Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
JP2023542867A (ja) 2020-09-11 2023-10-12 グリンプス バイオ， インコーポレイテッド 疾患の検出／診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出
CN113238050A (zh) * 2021-02-20 2021-08-10 吴炜 一种中性粒细胞胞外诱捕网的快速检测方法
CN113310963B (zh) * 2021-05-31 2023-12-01 四川大学华西医院 一种改进的中性粒细胞NETs免疫荧光检测方法
CN115267172A (zh) * 2022-07-29 2022-11-01 首都医科大学宣武医院 检测NSPs水平的物质在制备预测急性缺血性卒中患者预后产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120135443A1 (en) * 2009-06-26 2012-05-31 Schultz Gregory S Rapid Bed-Side Measurement of Neutrophil Elastase Activity in Biological Fluids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234131D1 (de) * 2001-08-01 2009-12-03 Cellomics Inc Neue fusionsproteine und molekulare bindungsassays
US8569275B2 (en) * 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
CA2567300A1 (en) * 2004-05-20 2005-12-01 Astellas Pharma Inc. Method for examining interstitial cystitis
US20080213404A1 (en) * 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
US20090298078A1 (en) 2006-09-29 2009-12-03 Leukocare Ag Method for the detection of an activation of the immune system or the extent of cell death
WO2010022281A1 (en) * 2008-08-20 2010-02-25 Greystone Pharmaceuticals, Inc. Methods for using human neutrophil elastase as an indicator of active wound infection
MX2012003644A (es) * 2009-10-02 2012-04-30 Astrazeneca Ab Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120135443A1 (en) * 2009-06-26 2012-05-31 Schultz Gregory S Rapid Bed-Side Measurement of Neutrophil Elastase Activity in Biological Fluids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTHONY J. O'DONOGHUE ET AL.: "Global identification of peptidase specificity by Multiplex Substrate Profiling", NATURE METHODS, vol. 9, no. 11, JPN6018003191, 2012, GB, pages 1095 - 1100, ISSN: 0003962443 *
BRICE KORKMAZ ET AL.: "Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases", PHARMACOLOGICAL REVIEWS, vol. 62, no. 4, JPN6018003186, 2010, pages 726 - 759, ISSN: 0003962441 *
HIROTO MATSUSE ET AL.: "Association of plasma neutrophil elastase levels with other inflammatory mediators and clinical feat", RESPIRATORY MEDICINE, vol. 101, no. 7, JPN6018003189, 2007, pages 1521 - 1528, ISSN: 0003962442 *
VOLKER BRINKMANN AND ARTURO ZYCHLINSKY: "Neutrophil extracellular traps: Is immunity the second function of chromatin?", J. CELL BIOL., vol. 198, no. 5, JPN6018003194, 2012, pages 773 - 783, ISSN: 0003962444 *

Also Published As

Publication number Publication date
US20160011209A1 (en) 2016-01-14
WO2014144572A2 (en) 2014-09-18
US9958459B2 (en) 2018-05-01
CN105339780A (zh) 2016-02-17
HK1214863A1 (zh) 2016-08-05
WO2014144572A3 (en) 2014-11-06
CA2906124A1 (en) 2014-09-18
EP2997352A2 (en) 2016-03-23
EP2997352A4 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
Agard et al. Inflammatory stimuli regulate caspase substrate profiles
JP2016519761A (ja) 好中球細胞外トラップにおけるプロテアーゼの基質プロファイリング
Perera et al. NSP4 is stored in azurophil granules and released by activated neutrophils as active endoprotease with restricted specificity
Jacobson et al. Autoregulation of the 26S proteasome by in situ ubiquitination
Stoehr et al. A SILAC-based approach identifies substrates of caspase-dependent cleavage upon TRAIL-induced apoptosis
US20210311059A1 (en) Methods of isolating barrel-like proteases and identifying peptides processed thereby
de Poot et al. Human and mouse granzyme M display divergent and species-specific substrate specificities
Siano et al. A comparative study of the biological activity of skin and granular gland secretions of Leptodactylus latrans and Hypsiboas pulchellus from Argentina
Zhang et al. Optimization of human dendritic cell sample preparation for mass spectrometry-based proteomic studies
US20100311114A1 (en) Preparation of samples for proteome analysis
Reed et al. Extracellular Biotransformation of β‐Endorphin in Rat Striatum and Cerebrospinal Fluid
Plasman et al. Probing the efficiency of proteolytic events by positional proteomics
Dubois et al. Dipeptidyl peptidase 9 (DPP9) from bovine testes: Identification and characterization as the short form by mass spectrometry
Tambyrajah et al. Cell cycle-dependent caspase-like activity that cleaves p27KIP1 is the β1 subunit of the 20S proteasome
Saidi et al. Targeted high-resolution quadrupole-Orbitrap mass spectrometry analyses reveal a significant reduction of tachykinin and opioid neuropeptides level in PC1 and PC2 mutant mouse spinal cords
Duzzi et al. [des-Arg1]-Proctolin: A novel NEP-like enzyme inhibitor identified in Tityus serrulatus venom
Van Domselaar et al. Proteomic profiling of proteases: tools for granzyme degradomics
EP4396579A2 (en) A method of detecting a population of macrophages
Vejayan et al. The role of conventional two-dimensional electrophoresis (2DE) and its newer applications in the study of snake venoms
JP6502854B2 (ja) ポリユビキチン化基質の同定方法
Tijani et al. Abundance of Proteases in Nigerian Echis ocellatus Venom Revealed through Qualititative Proteomic Analysis
Eichler et al. Check for updates Chapter 10
Araya Identifying Novel Apoptotic and Non-Apoptotic Substrates of Caspases
Picciani et al. Technical Brief: a novel strategy for enrichment of trabecular meshwork protease proteome
Wanner et al. GFAP Degradation in TBI: Linking Novel Modified Products to Astrocyte Pathology and Patient Outcome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190903